Tumor necrosis factor-related apoptosis ligand induces apoptosis in prostate cancer PC-3M cell line

Abstract

To study the effect of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) on PC-3M cell line, PC-3M cell line was incubated with gradient concentrations of TRAIL for 4–24 h. Annixin-V fluorescence staining and TUNEL method were employed to detect the apoptosis of PC-3M cells. The morphology of apoptotic PC-3M cells was observed by electron microscopy. The relationship between TRAIL concentrations and the percentage of apoptotic cells was evaluated by flow cytometry. The proliferation inhibitory ratio was calculated by using MTT colorimetry. Our results showed that apoptosis of PC-3M cells could be induced by treatment with TRAIL for at most 4 h. The results of flow cytometry and MTT colorimetry demonstrated a time- and concentration-dependent relationship between cell apoptosis rate and TRAIL concentration. It is concluded that apoptosis of PC-3M cells can be induced by TRAIL. Because of the selective killing effect of TRAIL on tumor cells, it may become a potential alternative for the treatment of advanced prostate cancer.

Keywords

TRAIL / cell apoptosis / prostate cancer / PC-3M

References

[1] PanG, O'RourkeK, ChinnaiyanA M, et al.. The receptor for the cytotoxic ligand TRAIL. Science, 1997, 276(5309): 111-111

[2] PittiR M, MarstersS A, RuppertS, et al.. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem, 1996, 271: 12687-12687

[3] ShettyS, GladdenJ B, HensonE S, et al.. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) upregulates death receptor 5 (DR5) mediated by NFkap-paB activation in epithelial derived cell lines. Apoptosis, 2002, 7(3): 413-413

[4] PlasilovaM, ZivnyJ, JelinekJ, et al.. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia, 2002, 16(1): 67-67

[5] KeaneM M, EttenbergS A, NauM M, et al.. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res, 1999, 59(3): 734-734

[6] VignatiS, CodegoniA, PolatoF, et al.. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer, 2002, 38(1): 177-177

[7] OzorenN, KimK, BurnsT F, et al.. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res, 2000, 60(22): 6259-6259

[8] ModurV, NagarajanR, EversB M, et al.. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression, implications for RTEN mutation in prostate cancer. J Biol Chem, 2002, 277(49): 47928-47928

[9] JensterG. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol, 2000, 191: 227-227

[10] SheridanJ P, MarstersS A, PittiR M, et al.. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 1997, 277: 818-818